A transforming N-ras gene has been cloned from acute myeloblastic leukemia bone marrow cells, in parallel with the N-ras gene derived from fibroblasts of the same patient. N-ras derived from fibroblasts lacked focus-forming activity in NIH/3T3 cells, indicating that gene activation in the leukemia cells must have occurred by a somatic event. Construction of chimeric molecules between the transforming and the normal N-ras genes and subsequent biological and sequence analysis of these constructs revealed that the transforming gene was altered by a point mutation changing amino acid 12 of the N-ras protein from glycine to aspartic acid.
A fraction of certain human tumors contain activated forms of the Ha-, Ki, or N-ras proto-oncogenes (1) (2) (3) (4) (5) (6) (7) (8) (9) . Activated ras genes can be identified biologically by their ability to induce transformation of NIH/3T3 cells in culture. Ha-and Ki-ras genes are homologous to the rat-derived oncogenes of the Harvey and Kirsten sarcoma viruses (10) , respectively, whereas the N-ras gene, a more recently identified member of the ras-gene family (6, 8, 11) , has not yet been found in a retrovirus.
The initial discovery of ras activation in human tumors involved Ha-ras (1-3, 12, 13) , but activated forms of this gene subsequently have been detected only rarely. More frequently, Ki-ras activation is seen, particularly in carcinomas of the lung and of the digestive tract (3, 14) . N-ras activation occurs in human tumors representing a broader histological spectrum and has been detected in neuroblastoma, sarcoma, various leukemias, teratocarcinoma, and melanoma (6, 8, 11, (15) (16) (17) (18) (19) . Cloning and sequence analysis of activated ras genes has revealed that the mechanism of activation involves a single base substitution that alters an amino acid of the corresponding p21 protein. This mechanism was first described for Ha-ras isolated from the bladder carcinoma lines EJ and T24, where amino acid 12 is altered (20) (21) (22) . More recently, a substitution at codon 61 has been reported in an Ha-ras gene from a lung carcinoma (23) . For the Ki-ras gene, the mutations so far identified by sequencing involve amino acid 12 (24, 25) , but in the two cases of N-ras activation analyzed, alterations of amino acid 61 were found (11, 26) .
It seems a plausible working hypothesis that altered human ras proto-oncogenes are involved in human carcinogenesis, in view of the fact that the transduced and altered forms of these genes are involved in retroviral malignancies in animals. As most work done to date has made use of human tissue culture lines, it is noteworthy that activated ras-genes have also been found in fresh human tumor specimensnamely Ki-ras, in lung, bowel, pancreas, rhabdomyosarcoma, and ovarian carcinoma (4, 14, 27, 28) , and N-ras, in patients with acute myeloblastic leukemia (8, 15, 16 We used the basic transfection protocol of Wigler et al. (29) . Briefly, 37.5 ,ug of high molecular weight DNA, with or without additional plasmid, phage, or chimeric DNA, were transfected onto NIH/3T3 cells that had been seeded at 5 x 105 cells per 100-mm dish the day before. The medium was changed twice weekly, and foci of morphologically transformed cells were counted after 14 days.
Preparation of High Molecular Weight DNA. Cells were lysed in 100 mM NaCl/10 mM EDTA/10 mM Tris HCI, pH 7.5/0.5% NaDodSO4 containing 200 ,g of proteinase K per ml and then were incubated overnight at 37°C. Lysates were extracted twice with buffer-equilibrated phenol, once with phenol/chloroform/isoamyl alcohol (24:24:1, vol/vol), and once with chloroform/isoamylalcohol (24:1) and then extensively dialyzed against 1 mM EDTA/10 mM Tris HCl, pH 7.5. DNA to be used for molecular cloning was, in addition, digested with DNase-free RNase.
Molecular Cloning. Cellular DNA preparations containing the normal or the transforming human N-ras gene were partially digested with EcoRI and then were sedimented through a 5-20% potassium acetate gradient. Fractions were collected and aliquots were screened by Southern blotting with probes specific for the 8.8-kilobase (kb) and 7.0-kb EcoRI fragments of the N-ras gene (6) . Those fractions that contained DNA of about 16 kb and that hybridized to both probes were used to construct a library in the phage vector L47.1 (30, 31) . Recombinants were selected in a P2 lysogen and those containing a full-length N-ras gene were identified by plaque-hybridization (32) .
Construction of Chimeric Genes. Appropriate restriction fragments from both the normal and the transforming N-ras gene (see Fig. 2 ) were isolated from low-melting-point agarose gels by phenol extraction at 65°C. About 250 ng of each purified fragment were mixed in appropriate combinations ( Fig. 2 ) and ligated overnight with T4 DNA ligase at 15°C. The DNA was precipitated with ethanol, redissolved in water, and used to transfect NIH/3T3 cells as described above.
Sequencing. DNA fragments to be sequenced were isolated from agarose gels by electroelution, cloned into the double-stranded form of phage M13mplO and/or M13mpll and used to transfect JM105 cells. Single-stranded DNA containAbbreviation: kb, kilobase(s).
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ing the insert was prepared from recombinant phages and sequenced by the dideoxynucleotide chain-termination method (33) .
RESULTS
The Patient's Fibroblast DNA Lacks Transforming Activity. To establish whether N-ras activation observed in a patient with acute myeloblastic leukemia (15) was present in the germ line or the result of a somatic event, we examined DNA from a fibroblast culture derived from a skin biopsy from this patient for its transforming activity (Table 1) . Fibroblast DNA lacked appreciable focus-forming activity: only one focus was observed in a total of 18 plates in three consecutive experiments. DNA prepared from this single focus did not contain human repetitive DNA when examined by Southern blot analysis (data not shown); hence, this focus was considered to be "spontaneous." The fibroblast DNA preparation was not inhibitory or toxic when it was tested as carrier DNA in conjunction with a Moloney sarcoma virus-derived plasmid (Table 1 ). These data indicate that N-ras activation in this patient was a somatic event.
Cloning of Activated and Normal N-ras Alleles. To determine the molecular nature of the N-ras activation, we cloned both the normal and activated N-ras genes. The source of the activated N-ras gene was DNA isolated from a secondcycle NIH/3T3 focus which contained the human gene integrated in a 5-to 10-fold amplified form (data not shown). The source of the normal N-ras gene was DNA isolated from the patient's skin fibroblasts established in tissue culture.
It had previously been shown that digestion of cellular DNA with the restriction enzyme EcoRI splits the N-ras gene into two fragments of about 8.8 and 7.0 kb (11, 26) . The 8.8-kb fragment contains the first two exons, and the 7.0-kb fragment contains exons III and IV. Thus, to clone fulllength genes, cellular DNA was partially digested with EcoRI and size-fractionated by gradient sedimentation, and fractions containing a full-length N-ras gene were identified by using probes specific for the 8.8-and 7.0-kb fragments (see ref. 26 ). These fractions then were used to construct libraries, and recombinant phages containing N-ras genes were identified. From unamplified libraries, we obtained three independent fibroblast-derived phage isolates (designated XSS17, XSS18, and XSS19) and three independent leukemia-derived isolates (designated XTR1, XTR2, and XTR4). All the clones were characterized by restriction analysis (data not shown); the maps showing sites relevant to this study (see below) are presented in Fig. 1 . EcoRI digests of phage containing the fibroblast allele(s) gave the expected 8.8-and 7.0-kb fragments. Two phages (XSS18 and XSS19) contained an additional fragment of about 2.3 kb whereas XSS17 contained a 1.8-kb fragment. These fragments are adjacent to the 3' end of the 7.0-kb fragment and to the 5' end of the 8.8-kb fragment, respectively (Fig. la) . Digestion of XTR1, XTR2, and XTR4 with EcoRI revealed no 7.0-kb fragment but rather a doublet of 8.8-kb that hybridized to both the 8.8-and 7.0-kb N-ras probes (data not shown). Further mapping studies indicated that in the secondary focus from which the activated allele had been cloned, the 3' EcoRI site of the 7.0-kb fragment had been lost, presumably during the transfection process. Hence, the third and fourth exons reside on a larger fragment, whose 3' EcoRI site is located within the mouse DNA and whose size is almost identical to the 8.8-kb fragment containing the first two exons (Fig. lb) . As can be seen from Fig. 1 , there is no obvious difference in the restriction maps of N-ras derived from the leukemic DNA and from the fibroblast DNA. However, when the independently derived recombinant DNA clones were tested in the transfection assay (Table 1) , it was found that all three leukemia-derived N-ras genes had transforming activity whereas none of the three fibroblast-derived genes did. We take this as further evidence that the activated N-ras in this patient was the result of a somatic mutation.
Analysis of Chimeric Molecules. To localize the site of the N-ras activation, chimeric molecules were constructed and tested for transforming activity. First, the BamHI/EcoRI and the EcoRI/Sac I subfragments (see Fig. 1 ) containing the first two and the last two exons, respectively, were isolated from XTR1 (activated allele) and from XSS17 (normal allele). These were then religated to generate four constructs (Fig. 2 the strategy shown in Fig. 3 . The nucleotide sequence was identical to the published N-ras sequence (11, 26) .. 
DISCUSSION
To understand the role of ras-gene activation in tumorigenesis, it is important to know the temporal relationship between the activation event and the disease process; i.e., whether activation occurs before, at the time of, or after the establishment of the malignant clone. Based on analysis of melanoma tissue culture lines, it has recently been argued (19) that the mutations underlying ras activation may merely reflect tumor heterogeneity that occurs in subclones of an already established tumor. In the acute myeloblastic leukemia case presented here, the transforming allele was present at the outbreak of the clinical disease phase (15) . As the transforming efficiency of the bone marrow DNA isolated at that time was comparable to efficiencies from cloned positive cell lines, it appears that the activated N-ras allele was present in most if not all the malignant myeloblasts. The results presented here show that the transforming allele was not present in the germ line but was generated somatically. Taken together, these data are consistent with the interpretation that N-ras activation was an early event in the natural history of this leukemia.
By analyzing chimeric molecules constructed from both the activated and the normal N-ras alleles, we have shown that the activating event is a point mutation affecting amino acid 12 of the p21 N-ras protein. Two N-ras mutations have been characterized, one from the neuroblastoma line SK-N-SH and one from the fibrosarcoma line HT1080, both of which involve an alteration at amino acid 61 (11, 26) . The mutation reported here, which affects position 12, is consistent with known Ha-ras and Ki-ras alterations in which activation accompanies replacement of glycine at this position (20-22, 24, 34) . While no Ki-ras activation involving amino acid 61 has been reported, it appears that positions 12 and 61 are critical for all three ras gene products. Indeed, an activated Ki-ras gene with a glycine at position 12 has been reported (35) and this activation may well turn out to be a position-61 change. The fact that all ras mutations observed to date occur in the codons for amino acids 12 and 61 suggests a direct biochemical way to detect ras-activation: by using mixed oligonucleotide probes specific for potential changes at these sites it may be possible to detect mutations by Southern blot analysis. In sickle cell anemia, where a single point mutation in the germ line is responsible for the disease, it has been possible by this method to distinguish normal and mutated alleles and identify the heterozygous carrier genotype (36) .
Why do mutations affecting amino acids at these two positions have such a dramatic effect, conferring transforming activity on a previously "benign" molecule? The gene products of viral Ha-and Ki-ras bind GTP (37) , and structural arguments have been presented suggesting that glycine-12 is intimately involved (38) . Since the ras-coded p21 protein binds to the inner surface of the plasma membrane (39, 40) , it may be part of a receptor complex that transmits mitotic signals to the nucleus. Structural alterations in the GTP-binding p21 domain may lock the receptor complex in an "on" configuration, resulting in unscheduled mitotic activity. Such a hypothetical model for p21 function is in accordance with the recent discoveries showing that the products of v-sis and verbB, two other viral oncogenes, correspond to a growth factor (platelet-derived growth factor) and a growth factor (epidermal growth factor) receptor, respectively (41) (42) (43) .
N-ras activation seems to occur predominantly in leukemias. It has been seen in the myelocytic leukemia line HL-60, in acute myeloblastic leukemia, but also in acute T-cell leukemia and in chronic myelocytic leukemia (8, (15) (16) (17) .
Other transforming genes detected in leukemias are Ki-ras, seen in one acute lymphocytic leukemia line (16) , and Blym (44) . Judging from these reports, N-ras activation in leukemias occurs in about 10-15% of the cases, comparable to the frequency of Ki-ras activation seen in colon and lung tumors (4, 14) . If ras activation is indeed a copathogenic event in leukemogenesis, then alternative pathogenic pathways must operate in the majority of cases. It is interesting in this context to note that ras activation occurs also in experimentally induced murine thymic leukemias, but with high frequency (45) . All tumors induced with N-methylnitrosourea contain activated N-ras genes, whereas x-ray-induced leukemias have activated Ki-ras genes (45) . It remains to be seen whether activation/non-activation of the individual ras genes in human tumors reflects a specific corresponding carcinogenic stimulus. Clearly, more work, particularly involving primary tumors, will be needed to establish whether a pathogenic role exists for ras activation. 
